Annexon, INC. (ANNX) — 10-K Filings
All 10-K filings from Annexon, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Annexon Pushes Two Late-Stage Drugs Amidst Mounting Losses
— Mar 30, 2026 Risk: high
Annexon, Inc. (ANNX) is a clinical-stage biopharmaceutical company focused on complement-mediated neuroinflammatory diseases, reporting no revenue and significa -
Annexon, Inc. Files 2024 10-K
— Mar 3, 2025 Risk: medium
Annexon, Inc. filed its 2024 10-K on March 3, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Brisbane, California, operates -
Annexon, Inc. Files 2023 Annual Report on Form 10-K
— Mar 26, 2024 Risk: medium
Annexon, Inc. (ANNX) filed a Annual Report (10-K) with the SEC on March 26, 2024. Annexon, Inc. filed its 2023 Form 10-K on March 26, 2024. The company is incor
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX